Mitigating Suicide Risk During the COVID-19 Pandemic Via Telehealth Using an Intensive Single Session of "Brief Skills for Safer Living"
Sponsor study identifier
interventional
77
1 country
1
Study Start
December 1, 2020
Actual (reported)Primary Completion
March 24, 2023
Actual (reported)Study Completion
March 24, 2023
Actual (reported)Mental health concerns have been on the rise since the onset of the COVID-19 pandemic. The pandemic has worsened risk factors for suicide, including job loss, anxiety, depression, and loneliness. Timely and easy access to mental health services is a dire need, and this study will test the efficacy and feasibility of a brief clinical intervention, Brief Skills for Safer Living (Brief-SfSL), at reducing suicide risk. The goal of this study is to investigate whether Brief-SfSL, delivered online, is a suitable, acceptable and effective method for reducing suicide risk and providing timely mental health services. The results from this study will provide vital insight into effective interventions for suicide risk that are accessible and can be widely distributed.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 24, 2023
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 23, 2020
Actual (reported)August 3, 2020
Actual (reported)December 1, 2020
Actual (reported)March 24, 2023
Actual (reported)March 24, 2023
Actual (reported)Change in suicidal ideation using Beck Scale for Suicide Ideation
Beck Scale for Suicide Ideation is a 21-item self-report scale that quantifies suicidal ideation. Items are scored 0 to 2 and yield a total score ranging from 0 to 38. Higher scores reflect greater severity of suicidal ideation.
From baseline to 3 months; also administered at screening, 1 week and 1 month
Change in depression symptoms using the Quick Inventory of Depressive Symptoms self-report scale (QIDS-SR)
From baseline to 3 months; also administered at 1 week and 1 month
Change in anxiety symptoms using the Generalized Anxiety Disorder 7-item scale (GAD-7)
From baseline to 3 months; also administered at 1 week and 1 month
Participants with current suicidal ideation (Beck Suicide Scale \>10) will undergo Brief-SfSLtherapy
Brief-SfSL is a single-session individual therapy adaptation of the core goals/principles of the 20-week SfSL group therapy. Brief-SfSL incorporates the SfSL guiding principles of emphasizing safety, attending to the therapeutic relationship, recognizing the participant as the expert in their own experience, taking a trauma-informed approach, working with emotions while recognizing the role of alexithymia, and incorporating solution-focused concepts. The goal is to increase a person's understanding and capacity to engage in what would enable them to keep safe, even if thoughts of suicide are present. The intervention procedure is dynamic, but includes 4 core tasks: 1) understanding the individual's suicidal experience, 2) skills building, 3) developing a safety plan, and 4) identifying obstacles to enacting or engaging with the safety plan.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
St. Michael's Hospital
Toronto, Ontario, M5B 1M8, Canada
Sakina Rizvi, PhD
Unity Health Toronto
77 participants (actual enrollment reported by the registry).
First Submitted
July 23, 2020
First Posted
August 3, 2020
Study Start
BRITEPath- Phase 2
Change in Acquired Capability of Suicide Scale (ACSS)
From baseline to 3 months; also administered at 1 week and 1 month
Change in Interpersonal Needs Questionnaire score
From baseline to 3 months; also administered at 1 week and 1 month
Change in Dimensional Anhedonia Rating Scale (DARS) score
From baseline to 3 months; also administered at 1 week and 1 month
Participant feedback on their experiences with specific aspects of the Brief-SfSL intervention
3 months
Contact the study team to confirm eligibility.
December 1, 2020
Actual (reported)Primary Completion
March 24, 2023
Actual (reported)Study Completion
March 24, 2023
Actual (reported)Last Updated
November 9, 2023
Record last verified: 2023-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: